Benchmark analyst Bruce Jackson lowered the firm’s price target on Biofrontera Inc. (BFRI) to $2.75 from $7 and keeps a Buy rating on the shares. After Q1 revenue of $8.6M lagged the firm’s $10.6M estimate, its new revenue estimate is $41.1M for 2025, down from $43.1M, notes the analyst, who adds that historic sales patterns would suggest that the “already seasonally heavy” Q4 will be “the key to this year’s revenue growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BFRI:
- Biofrontera’s Strategic Advancements and Promising Prospects Justify Buy Rating
- Biofrontera, Inc. Reports Q1 2025 Financial Results
- Biofrontera Inc. reports Q1 EPS (47c) vs. ($2.88) last year
- Biofrontera Inc. reports Q1 EPS (47c) vs. (71c) last year
- Biofrontera Inc. announces patent protection on Ameluz until 2043